Evidence map›Paper›PMID 41647448›Full record

ArticleAvicenna journal of phytomedicine2026

Immunosuppressant activity and morphological changes in

Fernanda Weyand Banhuk, Izabela Virginia Staffen, Fernanda Tomiotto-Pellissier, Bruna Taciane da Silva Bortoleti, Wander Rogério Pavanelli, Thaís Soprani Ayala, Rafael Andrade Menolli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fernanda Weyand BanhukLaboratory of Applied Immunology, Center of Medical and Pharmaceutical Sciences, State University of West Paraná, Cascavel, Paraná, Brazil.
Izabela Virginia StaffenLaboratory of Applied Immunology, Center of Medical and Pharmaceutical Sciences, State University of West Paraná, Cascavel, Paraná, Brazil.
Fernanda Tomiotto-PellissierBiosciences and Biotechnology Postgraduate Program, Carlos Chagas Institute, Curitiba, Paraná, Brazil.
Bruna Taciane da Silva BortoletiBiosciences and Biotechnology Postgraduate Program, Carlos Chagas Institute, Curitiba, Paraná, Brazil.
Wander Rogério PavanelliBiosciences and Biotechnology Postgraduate Program, Carlos Chagas Institute, Curitiba, Paraná, Brazil.
Thaís Soprani AyalaLaboratory of Applied Immunology, Center of Medical and Pharmaceutical Sciences, State University of West Paraná, Cascavel, Paraná, Brazil.
Rafael Andrade MenolliLaboratory of Applied Immunology, Center of Medical and Pharmaceutical Sciences, State University of West Paraná, Cascavel, Paraná, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The first-line drugs used for treating leishmaniasis are highly costly and aggressive. Extracts from Materials and Methods: Sequential extraction with hexane, dichloromethane, and methanol was performed to obtain extracts from Results: Isocordoin and lonchocarpine were identified in dichloromethane and hexane extracts. Dichloromethane (LDS), hexane (LHS), and methanolic (LMS) extracts inhibited promastigote cell growth (IC Conclusion: The results revealed that the activities of the

Indexed as

CytotoxicityLeishmaniasisLeishmanicidalLonchocarpineLonchocarpusSeed extracts

Identifiers

PMID41647448
PMCPMC12872069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.